Amphastar P (AMPH)

Currency in USD
23.18
-0.66(-2.77%)
Closed·
22.91-0.27(-1.16%)
·

AMPH Earnings

Latest Release
Aug 06, 2026
EPS / Forecast
0.91 / 0.63
Revenue / Forecast
183.9M / 179.71M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/09--/0.864--/197.44M----Free Sign Up
2026/060.910/0.630183.90M/179.71M+44.44%+2.33%Free Sign Up
2026/030.420/0.720171.20M/176.32M-41.67%-2.9%Free Sign Up
2025/120.730/0.930183.10M/191.76M-21.51%-4.52%Free Sign Up
2025/090.930/0.828191.84M/185.23M+12.36%+3.57%Free Sign Up
2025/060.850/0.740174.41M/173.95M+14.86%+0.26%Free Sign Up
2025/030.740/0.690170.53M/174.35M+7.25%-2.19%Free Sign Up
2024/120.920/0.970186.50M/192.69M-5.15%-3.21%Free Sign Up
2024/090.960/1.00191.20M/194.69M-4%-1.79%Free Sign Up
2024/060.940/0.772182.40M/170.96M+21.7%+6.69%Free Sign Up

All numbers in USD

Amphastar P Earnings Call Summary for Q2/2026

  • Amphastar Q2 2026 revenue hit $183.9M, beating estimates of $179.71M; gross margin improved to 51% from 50% year-over-year.
  • BAQSIMI prescriptions rose 17% despite 3% sales decline to $45.5M due to pricing pressure and 340B-related discounts.
  • New ipratropium bromide inhalation product generated $8.4M since April launch; glucagon sales plunged 42% amid increased competition.
  • Company reaffirmed mid-to-high single-digit sales growth guidance for 2026; expects $2M-$3M quarterly IMS facility remediation costs.
  • Insulin aspart biosimilar remains on track for 2027 launch; $100M milestone payment owed to Eli Lilly after BAQSIMI sales threshold.
Last Updated: 2026-08-06, 07:08 p/m
Read Full Transcript

FAQ

What Is Amphastar P's Earnings Per Share (TTM)?

The Amphastar P EPS (TTM) is 1.69.

When Is The Next Amphastar P Earnings Date?

Amphastar P will release its next earnings report on Nov 09, 2026.

What Is Amphastar P’s Revenue Forecasts For Upcoming Quarters?

Amphastar P’s revenue forecast is 197.44M.

How Did Amphastar P React to the Company's Latest Earnings Report?

Amphastar P reported a +44.44% EPS surprise and a +2.33% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 2.67%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.